Stay updated on Opregen in Geographic Atrophy Clinical Trial
Sign up to get notified when there's something new on the Opregen in Geographic Atrophy Clinical Trial page.

Latest updates to the Opregen in Geographic Atrophy Clinical Trial page
- Check2 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 removed on the page; this is a minor metadata update and does not change study content, eligibility criteria, or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded the label Last Update Posted (Estimated) next to the update timestamp to indicate the estimate.SummaryDifference0.1%

- Check23 days agoChange DetectedAdded multiple study locations across California, Florida, Maryland, Missouri, Ohio, Pennsylvania, Tennessee, Texas, Virginia, and Washington. Updated eligibility criteria to require BCVA between 29 and 60 ETDRS letters and OpRegen dosing up to approximately 200,000 cells; revision 3.3.3 and a new Last Update Posted timestamp were recorded.SummaryDifference2%

- Check44 days agoChange DetectedA new 'Last Update Posted (Estimated)' field has been added to the Study Record Dates, and the previous 'Last Update Posted' field has been removed.SummaryDifference0.1%

- Check51 days agoChange DetectedAdded an auto-fill note for Publications indicating PubMed-derived articles may not be related to the study, and updated last update information and revision to v3.3.2; previous PubMed notes and an estimated update timestamp were removed.SummaryDifference0.4%

- Check58 days agoChange DetectedRemoved the government funding status notice, a non-critical item, while core study details remain unchanged; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Opregen in Geographic Atrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Opregen in Geographic Atrophy Clinical Trial page.